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Background and Objective. Serum erythropoietin
(sEpo) concentration depends primarily on the rate of
renal production in response to hypoxia. However,
sEpo levels increase inappropriately after conditioning
for autologous stem cell transplantation (ASCT)
before progressively returning to adequate levels. We
investigated the possible influence of erythropoietic
activity on these observations. 
Design and Methods. Forty patients undergoing an
ASCT, 8 with bone marrow (BMT) and 32 with periph-
eral blood stem cells (PBSC), were separated into 3
groups. Group 1 was formed of the 8 BMT patients
(median time to 1% reticulocytes: 39 days), group 2
of 16 PBSC patients with relatively slow erythroid
engraftment (‡ 15 days to 1% reticulocytes, median
19 days) and group 3 of 16 PBSC patients with
prompt erythroid recovery (< 15 days to 1% reticulo-
cytes, median 13 days). Marrow erythroid activity
was assessed by serum transferrin receptor levels
(sTfR). Serum Epo (sEpo) levels were expressed in
relation to the degree of anemia as observed/pre-
dicted (O/P) ratios of (O/P) log (sEpo). 
Results. Serum sTfR levels decreased by more than
50% in all 3 groups after conditioning, reaching their
nadir on day 7. Nadir values doubled by day 28 in
group 3, day 60 in group 2, but not within 100 days
in group 1. O/P sEpo ratios increased inappropriate-
ly in all 3 groups after conditioning but then declined
at very differing speeds in the 3 groups. In group 1,
ratios remained above 1.10 through to day 28 and
above 1.00 through to day 42, before leveling off at
around 1.00 thereafter. In group 2, ratios remained
above 1.00 through to day 14, than decreased to a
minimum of 0.89 by day 42 before returning to 1.00
by day 100. In group 3, ratios decreased to 0.84 by
day 21 and remained below 0.90 thereafter. 
Interpretation and Conclusions. We conclude that
sEpo levels are not only influenced by tissue oxy-
genation but also depend on the mass of erythroid
precursors in the bone marrow. This may be the main
explanation for the observed changes in sEpo levels
during ASCT.
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Erythropoietin (Epo) is predominantly producedby the kidney but as there are no pre-formedstores of Epo any increase in the rate of pro-
duction must be preceded by Epo gene transcrip-
tion.1 Epo production is regulated by a feedback
mechanism by which the blood oxygen content is
maintained at a constant level through the function
of a kidney oxygen sensor.2-4 The major determinant
of Epo production is therefore the circulating red cell
mass, and serum Epo levels thus increase exponen-
tially as the hemoglobin or hematocrit decreases.5,6
The adequacy of serum Epo levels is best assessed
by the observed/predicted (O/P) ratio, a value below
1 indicating that Epo production is lower than
expected for the degree of anemia.7 However, a num-
ber of clinical observations suggest that the regula-
tion of serum Epo levels depends not only on the rate
of Epo production but also on the red cell precursor
mass. Abnormally high serum Epo levels have been
encountered in patients with marrow aplasia8-11 and
dramatic changes have been observed at the begin-
ning of vitamin B12 or iron therapy before any
increase in hemoglobin could occur.11-13
In particular, inappropriately high serum Epo lev-
els were observed after intensive chemotherapy.14,15
These levels were even higher after conditioning
before autologous or allogeneic bone marrow trans-
plantation (BMT).11,15-25 Serum Epo levels usually
peaked one week after BMT, before progressively
returning to values appropriate for the degree of ane-
mia in autologous BMT recipients.18,23-25 However,
after allogeneic BMT, serum Epo levels rapidly
became inadequately low and remained so for sev-
eral months.18,22,24,25 This was shown to be the con-
sequence of cyclosporine administration26,27 but oth-
er factors, such as GVHD18,21,24,25 or CMV infec-
tion18,24 are also involved. Therefore, autologous –
but not allogeneic – hematopoietic stem cell trans-
plantation (ASCT) represents an ideal setting for
investigating the effect of acute variations in the ery-
throid precursor mass on serum Epo levels. In this
study, we undertook an examination of the tempo-
ral relationship between erythropoietic activity and
serum Epo levels during autologous transplantation
of bone marrow or peripheral blood stem cells with
varying speeds of engraftment.
Materials and Methods
Patients
We studied a total of 40 patients, 20 women and 20
men, aged 6 to 61 yrs, undergoing an ASCT for high-
risk malignancies. There were 4 patients with Hodgk-
in’s disease, 13 with non-Hodgkin’s lymphoma, 7 with
multiple myeloma, 2 with acute lymphocytic leukemia,
1 with acute myelogenous leukemia, 8 with breast can-
cer and 5 with other miscellaneous solid tumors. Con-
ditioning before transplantation consisted of various
combinations of high-dose chemotherapy with (n=7)
or without (n=33) total body irradiation (TBI). No
patient experienced severe liver toxicity. Eight patients
were transplanted with autologous bone marrow
(BMT) and 32 with autologous peripheral blood stem
cells (PBSC). Post-transplant G-CSF (5 µg/kg) was giv-
en to 28 PBSC patients but to none of the BMT
patients. All patients survived beyond day 100. Eight
of them died later, 6 of their malignant disease, 1 of
sepsis and 1 of a second cancer. Patients were sepa-
rated into 3 groups on the basis of their speed of ery-
throid engraftment. Group 1 consisted of the 8 BMT
patients (median time to 1% reticulocytes 39 days),
group 2 of 16 PBSC patients with relatively slow ery-
throid engraftment ( ‡ 15 days to 1% reticulocytes,
median 19 days) and group 3 of 16 PBSC patients
with prompt erythroid recovery (< 15 days to 1% retic-
ulocytes, median 13 days).
Laboratory analyses
Complete blood counts were determined in a Tech-
nicon H2 cell counter (Bayer, Tarrytown, NJ, USA).
Percentages of reticulocytes were obtained by an
automated cytofluorometric method.28 Serum soluble
transferrin receptor (sTfR), a quantitative measure of
total erythropoietic activity, was measured by an ELISA
in which each sample was run in triplicate.7,29
Mean±SD in 165 normal subjects was 5,000±1,050
ng/mL. Serum erythropoietin (Epo) levels were mea-
sured by a commercially available radioimmunoassay
(Incstar Corp., Stillwater, MN, USA). Based on
regression equations obtained in appropriate refer-
ence subjects between Hct on the one hand and log
(Epo) on the other, predicted log (Epo) values were
derived for each Hct and observed/predicted (O/P)
ratios of O/P Epo values were calculated.7 The 95%
confidence limits for O/P Epo in reference subjects
were 0.80-1.20.7
Statistical methods
Student's t-tests, with pooled or separated vari-
ances as appropriate, were used to compare two
groups. Analyses of variance (ANOVA), with Snede-
cor's F-test or Welch's test as appropriate, were used
to compare more than two groups. Times to hema-
topoietic recovery were studied by life table analyses
and Wilcoxon rank tests were used for comparison
between groups. Statistical analyses were done using
Microsoft Excel (Microsoft Corp, Redmont, WA,
USA) and Graphpad Prism (Graphpad Software, San
Diego, CA, USA) programs.
Results
The speed of engraftment was significantly different
among the 3 groups. By definition, erythroid engraft-
ment (as assessed by time to reach 1% reticulocytes)
was slower in group 2 than in group 3, and even more
so in BMT patients (Figure 1). The speed of platelet
engraftment showed the same differences between the
3 groups (Figure 2). Neutrophil recovery was slightly
faster in group 3 than in group 2, but was significant-
ly delayed in group 1 (Figure 3). 
Figure 4 shows the evolution of mean Hct values in
the 3 groups, confirming the faster erythroid engraft-
ment in group 3 compared to group 2. Hct values in
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Figure 1. Time to reach 1% reticulocytes in group 1 (BMT),
group 2 (PBSC with slow erythroid engraftment) and group
3 (PBSC with rapid erythroid engraftment) (p<0.0001).
Figure 2. Time to reach 25,000 platelets without further
transfusion in group 1 (BMT), group 2 (PBSC with slow ery-
throid engraftment) and group 3 (PBSC with rapid erythroid
engraftment) (p<0.0001).
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BMT patients were relatively higher because the trans-
fusion trigger in these patients was a Hct value below
30% instead of 27% for PBSC patients. Serum sTfR
levels decreased by more than 50% in all 3 groups
after conditioning to reach their nadir on day 7.
Nadir values doubled by day 28 in group 3, day 60 in
group 2, but not within 100 days in group 1 (Figure
5). Before conditioning, O/P Epo ratios were similar
in the 3 groups (0.94, 0.96, and 0.96, in groups 1, 2
and 3, respectively). After conditioning all 3 groups
showed an abnormal elevation of O/P Epo ratios to
1.20, 1.16 and 1.15, respectively (ns). After trans-
plantation, O/P Epo ratios declined at very different
speeds in the 3 groups (Figure 6). In group 1, ratios
remained above 1.10 through to day 28 and above
1.00 through to day 42, before leveling off at around
1.00 thereafter. In group 2, ratios remained above
1.00 through to day 14, than decreased to a mini-
mum of 0.89 by day 42 before returning to 1.00 by
day 100. In group 3, ratios decreased to 0.84 by day
21 and remained below 0.90 thereafter. 
Discussion
Serum Epo levels may vary considerably.5,6,30 Levels
are usually between 10 and 20 mU/mL in normal
subjects, may decrease somewhat in primary poly-
cythemia, but increase exponentially when an ane-
mia develops below an Hct of 30-35%. Therefore, a
serum Epo value must always be evaluated in relation
to the degree of anemia, for instance through the
O/P ratio.7 Epo levels inappropriately low for the
degree of anemia are encountered not only in renal
Figure 3. Time to reach 500 neutrophils in group 1 (BMT),
group 2 (PBSC with slow erythroid engraftment) and group
3 (PBSC with rapid erythroid engraftment) (p<0.0001).
Figure 4. Mean Hct values, expressed as percentages of
pre-transplant Hct, in group 1 (BMT), group 2 (PBSC with
slow erythroid engraftment) and group 3 (PBSC with rapid
erythroid engraftment) up to day 100 post-transplant.
Figure 5. Mean serum sTfR levels, expressed as percent-
ages of day 7 nadir values, in group 1 (BMT), group 2 (PBSC
with slow erythroid engraftment) and group 3 (PBSC with
rapid erythroid engraftment) up to day 100 post-transplant.
Figure 6. Median O/P Epo ratios in group 1 (BMT), group 2
(PBSC with slow erythroid engraftment) and group 3 (PBSC
with rapid erythroid engraftment) up to day 100 post-trans-
plant.
failure,31 but also in a number of other conditions,
particularly in the anemia of chronic disorders,32
including the anemia associated with cancer.33 Inap-
propriately high serum Epo levels are often observed
in secondary polycythemia, a feature permitting its
diagnostic separation from primary polycythemia.34
Such inappropriately high levels are also encountered
in patients with aplastic anemia (erythropoietic activ-
ity < 0.6 times normal) compared to subjects with
iron deficiency anemia (erythroid activity relatively
normal) or thalassemia intermedia (erythroid activi-
ty > 2 times normal).8-11
High serum Epo levels are also observed transiently
after intensive chemotherapy, whether followed by
bone marrow transplantation or not, without con-
comitant changes in hemoglobin or hematocrit.11,14-25
As shown again in our study, the peak Epo values are
observed 7 days after transplantation, i.e. about 14
days after the start of the conditioning regimen, at
the time of the nadir of erythropoietic activity. As
there are no preformed stores of Epo, this cannot be
due to a sudden release of Epo by the kidney medi-
ated by cytostatic drugs. Some other speculations
have been offered as explanations for this phenome-
non.20 Cytotoxic therapy could cause a direct injury
to the Epo-producing cells mimicking hypoxia. The
blood flow to the kidney and/or liver could be altered
so as to expose Epo-producing cells to hypoxia. As
protein synthesis and gene transcription are neces-
sary for the normal degradation of Epo mRNA, it is
also possible that cytotoxic therapy could enhance
Epo mRNA stability. However, some experimental
data contradict these hypotheses. Cobalt-induced
Epo production was markedly suppressed 18-36
hours after the infusion of the alkylating agents chlo-
rambucil or thiotepa through dog kidneys isolated in
situ.35 In cultures of the hepatoma cell line HepG2,
vincristine as well as the RNA synthesis-inhibiting
drugs daunorubicin, cyclophosphamide, ifosfamide,
and CDDP dose-dependently decreased Epo pro-
duction, while the DNA synthesis-inhibiting drugs
methotrexate and cytosine-arabinoside did not have
inhibitory properties.36,37 These results suggest that
chemotherapeutic agents do not stimulate Epo pro-
duction locally.
These findings thus point to an inverse relationship
between marrow erythropoietic activity and serum
Epo levels: the higher the number of erythroid pre-
cursors, the lower the serum Epo value. As Epo exerts
its action on target cells after binding to a specific
Epo receptor,38 it is tempting to speculate that serum
Epo levels may partly depend on the rate of Epo uti-
lization by Epo receptor-bearing cells, primarily ery-
throid precursors.11,39 Therefore, severe myelosup-
pression following the conditioning regimen could
disrupt the usual Epo degradation pathway and pro-
voke a surge of serum Epo concentration through
prolonged Epo life span. Similarly, marrow recovery
after ASCT would restore Epo utilization by erythroid
cells, thus progressively returning Epo levels to a
range appropriate for the degree of anemia. Further-
more, the duration of this correction phase would
depend on the speed of engraftment: the faster the
erythroid recovery, the shorter the time necessary for
a complete return to adequate Epo levels. Indeed,
our patients with particularly intense erythropoietic
activity (group 3) even exhibited somewhat decreased
Epo levels during their recovery phase. All these sur-
mises are well illustrated by the mirror evolutions of
serum Epo (Figure 6) and sTfR (Figure 5) levels in our
3 study groups.
The idea that marrow utilization influences serum
Epo levels was initially based on the observation that
radiation-induced marrow hypoplasia was associated
with a slower decline of serum Epo levels induced by
hypoxia.40 However, the rate of Epo disappearance
from the plasma of dogs with normal, hypoplastic or
hyperplastic marrow, was later shown to be similar,
whether the experiment was performed in nephrec-
tomized41 or unmanipulated42 animals. Epo accumu-
lation in the kidney and bone marrow of rats was min-
imal after intravenous injection of a tracer dose of
rHuEpo.43 Furthermore, erythropoietin life span was
similar in normal rats and in rats with bone marrow
suppressed by cyclophosphamide or hypertransfusion
or stimulated by hemolysis or bleeding.44 The phar-
macokinetics of rHuEpo in hemodialysis patients was
not different before and after 6 weeks of treatment
with rHuEpo.45 Therefore, variations observed in
serum Epo levels after intensive chemotherapy cannot
simply be explained by changes in Epo consumption
by the bone marrow. Indeed, experiments on hypo-
baric hypoxemia in mice previously treated or untreat-
ed with rHuEpo suggested that variations in plasma
Epo levels during periods of rapidly expanding ery-
thropoiesis are the reflection of a decrease in the rate
of production rather than in the rate of utilization by
proliferating erythroid precursors.46 Therefore, where-
as it is indisputable that marrow erythropoietic activ-
ity independently influences serum Epo levels, it is pos-
sible that this happens through some other (yet to be
elucidated) mechanism by which marrow erythro-
poiesis influences the rate of Epo production by the
kidney.  Some other factors linking the erythron to Epo
production may also exist. For instance, products
resulting from red cell hemolysis may indirectly stim-
ulate marrow erythropoietic activity as well as renal
Epo production.47,48
We conclude that serum Epo levels are not only
influenced by tissue oxygenation but also depend on
the mass of erythroid precursors in the bone marrow.
This is particularly true in the course of ASCT, but
should also be taken into account when interpreting
the adequacy of a serum Epo value in other situa-
tions. It remains to be determined whether the ery-
throid precursor mass acts directly by utilizing circu-
lating Epo or indirectly by influencing the rate of Epo
production.
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